Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97553 | 0.81 | ITGB2 (0.41) | ITGB2ICAM1ITGAL | |
| SCHEMBL4524534 | 0.80 | IMPDH2 (0.41) | LTB4RLTB4R2CYP19A1DRD2DRD3 | |
| SCHEMBL5541762 | 0.72 | LTB4R (0.47) | LTB4RLTB4R2CYP19A1DRD2DRD3 | |
| SCHEMBL18570198 | 0.68 | LTB4R (0.43) | LTB4RLTB4R2CYP19A1DRD2DRD3 | |
| SCHEMBL8086768 | 0.68 | LTB4R (0.43) | LTB4RLTB4R2CYP19A1DRD2DRD3 | |
| SCHEMBL24090507 | 0.68 | LTB4R (0.43) | LTB4RLTB4R2CYP19A1DRD2DRD3 | |
| SCHEMBL507362 | 0.68 | LTB4R (0.43) | LTB4RLTB4R2CYP19A1DRD2DRD3 | |
| SCHEMBL691833 | 0.68 | LTB4R (0.43) | LTB4RLTB4R2CYP19A1DRD2DRD3 | |
| SCHEMBL19268289 | 0.68 | LTB4R (0.51) | LTB4RLTB4R2CYP19A1DRD2DRD3 | |
| SCHEMBL10820255 | 0.68 | LTB4R (0.43) | LTB4RLTB4R2CYP19A1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254873-B1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8664217-B2 | Benzodiazepine compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-03-04 | — | — | US | disclosed |
| US-20130040941-A1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. | 2013-02-14 | — | — | US | disclosed |
| US-8338406-B2 | Benzodiazepine compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20100331317-A1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331317-A1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | KCNA5, KCNA1, KCNAB1 | LTB4R 630/4885LTB4R2 762/4885CYP19A1 519/4885 |
| US-20130040941-A1 | BENZODIAZEPINE COMPOUND AND PHARMACEUTICAL COMPOSITION | KCNA5, KCNA1, KCNAB1 | LTB4R 630/4885LTB4R2 762/4885CYP19A1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.